Dr. Frank Wiegand is Chief Medical Officer of Beckley Psytech Ltd., a UK-based, privately held, clinical-stage biopharmaceutical company that develops psychotherapy-assisted psychedelics into licensed medicines for the treatment of neuropsychiatric conditions with high unmet medical need.
Dr. Wiegand assumed the position of CMO in September of 2021. As CMO, he leads the clinical R&D and regulatory functions and is responsible for all aspects of the clinical development of the company’s assets.
Dr. Wiegand is a German-trained Neurologist and Neuroscientist with 22 years of experience in the biopharmaceutical industry, acquired mainly at Janssen Pharmaceuticals (a Johnson & Johnson subsidiary), where he most recently held the position of Vice President, Global Medical Affairs in Neuroscience. Over his two decades at J&J, he has held positions of increasing responsibility in marketing and sales, global strategic marketing, medical affairs, and market access in addition to acquiring extensive research and development experience across the organization.
During his career, Dr. Wiegand has worked on more than 30 different new molecular entities across multiple neurological and psychiatric conditions, most recently contributing to the development and subsequent approval of Esketamine, an NMDA receptor antagonist, which was approved for the therapy of treatment resistant depression and suicidality. He brings his extensive experience and knowhow gained from leading multiple functions across the continuum of pharmaceutical research, development, and commercialization to the Beckley Psytech executive team.
Dr. Wiegand received his M.D. and PhD. from the Heinrich Heine University of Düsseldorf, Germany and completed his fellowship training as a neurologist at the University of Essen, Germany. He completed his post-doctoral fellowship in neuropharmacology, specifically cerebral ischemia, at the Humboldt University Berlin, Germany, with funding from the German Stroke Research Foundation. In 2002 he received a Postgraduate Certificate in Business Administration from the Herriot Watt University, Scotland.
Dr. Wiegand assumed the position of CMO in September of 2021. As CMO, he leads the clinical R&D and regulatory functions and is responsible for all aspects of the clinical development of the company’s assets.
Dr. Wiegand is a German-trained Neurologist and Neuroscientist with 22 years of experience in the biopharmaceutical industry, acquired mainly at Janssen Pharmaceuticals (a Johnson & Johnson subsidiary), where he most recently held the position of Vice President, Global Medical Affairs in Neuroscience. Over his two decades at J&J, he has held positions of increasing responsibility in marketing and sales, global strategic marketing, medical affairs, and market access in addition to acquiring extensive research and development experience across the organization.
During his career, Dr. Wiegand has worked on more than 30 different new molecular entities across multiple neurological and psychiatric conditions, most recently contributing to the development and subsequent approval of Esketamine, an NMDA receptor antagonist, which was approved for the therapy of treatment resistant depression and suicidality. He brings his extensive experience and knowhow gained from leading multiple functions across the continuum of pharmaceutical research, development, and commercialization to the Beckley Psytech executive team.
Dr. Wiegand received his M.D. and PhD. from the Heinrich Heine University of Düsseldorf, Germany and completed his fellowship training as a neurologist at the University of Essen, Germany. He completed his post-doctoral fellowship in neuropharmacology, specifically cerebral ischemia, at the Humboldt University Berlin, Germany, with funding from the German Stroke Research Foundation. In 2002 he received a Postgraduate Certificate in Business Administration from the Herriot Watt University, Scotland.
Speaking In
9:00 AM - 10:00 AM (PDT)
Thursday, June 16
The psychedelics industry has evolved from a stigmatized counterculture phenomenon to a…
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
